RxDoctor Payments Data

van van

Physician Assistant · Wichita, KSNPI 1457081770

Payments from drug & device makers

$3,652in general payments, 2019–2025

Across 150 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$465
  • Otsuka America Pharmaceutical, Inc.$418
  • AbbVie$349
  • Alkermes, Inc.$269
  • Corium, LLC$253
  • Idorsia Pharmaceuticals US Inc$238
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$3,54397%
  • Education$1093%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,652 in reported general payments places this provider in the 85th percentile of 1,016 physician assistant providers in Kansas.

See all physician assistant providers in Kansas

Medicare billing

Part B allowed, 2024
$11,691
Medicare patients
40
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$30,722
TrintellixVortioxetine Hydrobromide12$5,868
Aripiprazole32$1,392
Duloxetine Hcl74$964
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine20$926
Desvenlafaxine Succinate ErDesvenlafaxine Succinate27$827
Bupropion XlBupropion Hcl53$734
Sertraline Hcl98$641
Clonazepam53$566
Trazodone Hcl140$476
Olanzapine27$464
Fluoxetine Hcl51$421
Quetiapine Fumarate52$411
Buspirone Hcl40$400
Zolpidem Tartrate31$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$349$30,72221 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$87$5,86812 claims
Almatica Pharma LLCSertraline Hcl$156$64198 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,016 physician assistant providers in Kansas.

Other physician assistant in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →